et the question remains on the way to predict these complications. It’s relevant to consider prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal pain with no significant alterations on coagulation profile or other danger components should really raise the awareness for mesenteric thrombosis. In fact, handful of circumstances of intestinal thrombosis exist inside the literature contemplating our patient certainly one of the first instances of subacute mesenteric venous thrombosis in a non-severe COVID-19 patient. Far more case reports and descriptive data are necessary within the literature to enhance the index of suspicion for these kinds of complications.research concluding that there’s no difference in collateral formation, recanalization and mortality, regardless of whether anticoagulation had been prescribed or not. These findings emphasize the predominant part of inflammation, rising uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are affected, anticoagulation seems a reasonable attitude, taking into consideration the threat of Aurora C Inhibitor custom synthesis hepatic decompensation and bowel ischemia. Far more research are needed to consolidate this evidence and to establish well-defined recommendations in other scenarios (e.g., isolated thrombosis of splenic vein, as within this case).V T E D I AG N O S I S PB1175|Detection of Appropriate Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Assessment and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Mbuagbaw2;PB1174|Does Anticoagulation Have an effect on Outcome of Splenic Vein Thrombosis in Acute Pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is actually a wellestablished complication of acute pancreatitis (AP) and might impact splenic, portal and superior mesenteric veins, either isolated or in mixture. Its pathogenesis is closely related to inflammation, Aurora B Inhibitor Compound leading to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Strategies: Collection of clinical information in SCl ico application. Final results: A 47-year-old female patient, with antecedents of prior AP secondary to hypertriglyceridemia, was admitted to emergency division with pain in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, over the previous handful of hours. Via clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, four days later, resulting from clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg as soon as day-to-day at discharge. 3 months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Taking into consideration this substantial collateral circulation, total recanalization was no longer expected. Anticoagulation was maintained to get a total period of 6 months. Conclusions: Management of thrombosis in AP remains challenging. There is no consensus on anticoagulation in this setting, with someM. Crowther2; A. Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana
